• This record comes from PubMed

Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality

. 2020 Sep-Oct ; 34 (5) : 3027-3028.

Language English Country Greece Media print

Document type Journal Article

Persistent link   https://www.medvik.cz/link/pmid32871847

The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.

See more in PubMed

Smetana K Jr., Brábek J. Role of interleukin-6 in lung complications in patients with COVID-19: Therapeutic implications. In Vivo. 2020;34:1589–1592. doi: 10.21873/invivo.11947. PubMed DOI PMC

Brábek J, Rosel D, Smetana K, Fernandes M. Repurposing of bazedoxifene to prevent cytokine storm in COVID-19 patients (electronic response to Moore JB and Joone CH: Cytokine release syndrome in severe COVID-19) Science. 2020;368:473–474. doi: 10.1126/science.abb8925. PubMed DOI

Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J Med Chem. 2014;57:632–641. doi: 10.1021/jm401144z. PubMed DOI

Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C, Huo S, Duan J, Tao J, Zhai M, Luo P, Guo J, Tian L, Mageta L, Jou D, Zhang C, Li J, Zhai M, Luo P, Guo J, Tian L, Mageta L, Jou D, Zhang C, Li C, Lin J, Lv J, Li S, Lin L. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma. Cancer Sci. 2019;110:950–961. doi: 10.1111/cas.13940. PubMed DOI PMC

Andersson A, Bernardi AI, Stubelius A, Nurkkala-Karlsson M, Ohlsson C, Carlsten H, Islander U. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology. 2016;55:553–563. doi: 10.1093/rheumatology/kev355. PubMed DOI PMC

Thilakasiri P, Huynh J, Poh AR, Tan W, Nero TL, Tran K, Parslow AC, Afshar-Sterle S, Baloyan D, Hannan NJ, Buchert M, Scott AM, Griffin MD, Hollande F, Parker MW, Putoczki TL, Ernst M, Chand AL. Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. EMBO Mol Med. 2019;11:e9539. doi: 10.15252/emmm.201809539. PubMed DOI PMC

Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Identification of antiviral drug candidates against SARS-CoV- 2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64:e00819–20. doi: 10.1128/AAC.00819-20. PubMed DOI PMC

Bakowski M, Beutler N, Chen E, Nguyen TH, Kirkpatrick MG, Parren M, Yang L, Ricketts J, Gupta AK, Hull MV, Schultz PG, Burton DR, Chatterjee AK, McNamara CW, Rogers TF. Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19. BioRxiv. 2020 doi: 10.1101/2020.06.16.153403. DOI

Coronavirus: Using European supercomputing, EU-funded research project announces promising results for potential treatment. Available at: https://ec.europa.eu/commission/presscorner/detail/en/IP_20_890 [Last accessed on July 1st, 2020]

Find record

Citation metrics

Archiving options